ArticleCell death discovery2026
Wnt signaling-mediated activation of cancer cell stemness in thoracic SMARCA4-deficient undifferentiated tumor cells.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) represent a distinct and highly aggressive malignancy characterized by SMARCA4 deficiency, poor prognosis, and resistance to chemotherapy. The lack of clarity regarding the regulatory mechanisms underlying this disease has hindered the development of standardized treatment guidelines. In this study, we analyzed clinical samples and found significantly elevated levels of cancer stem cell markers, including SOX2, CD34, c-Myc, and EpCam, in thoracic SMARCA4-UT, which were further confirmed in SMARCA4-deficient non-small cell lung cancer (NSCLC) cells. Furthermore, SMARCA4 knockdown in NSCLC cells promoted cell proliferation, migration, invasion, and tumorsphere formation in vitro, as well as enhanced tumor growth in a mouse model in vivo. RNA sequencing analysis of SMARCA4-deficient cells revealed the upregulation of a subset of genes, including Wnt10A, and activation of Wnt signaling. This was validated through SMARCA4-ChIP-seq and SMARCA4-ChIP-PCR analyses, Wnt activity reporter assays, and subcellular distribution analysis of β-catenin. Subsequent studies using a small molecule Wnt inhibitor in SMARCA4-deficient cells and thoracic SMARCA4-UT patient-derived organoids demonstrated induction of apoptosis, inhibition of cell stemness, and suppression of tumor cell growth. These results suggest the potential for developing a novel therapeutic strategy targeting cancer stem cells for the treatment of thoracic SMARCA4-UT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.